189132-01-2

Basic information

• Product Name: (4-IODO-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: (4-IODO-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER;tert-Butyl 4-Iodobenzylcarbamate
• CAS NO: 189132-01-2
• Molecular Formula: C₁₂H₁₆INO₂
• Molecular Weight: 333.17
• Mol File: 189132-01-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (4-IODO-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (4-IODO-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER(189132-01-2)
• EPA Substance Registry System: (4-IODO-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER(189132-01-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 189132-01-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(4-IODO-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as an intermediate in the synthesis of pharmaceuticals for its role in creating new chemical compounds that can be utilized in the development of medications.
Used in Agrochemical Industry:
(4-IODO-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as an intermediate in the synthesis of agrochemicals to aid in the production of new compounds that can be applied in agricultural settings for pest control and crop protection.
Used in Organic Synthesis:
(4-IODO-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as a building block in organic synthesis for its ability to contribute to the formation of complex organic molecules, which can be applied across different chemical and industrial processes.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 68819-84-1 tert-butyl N-(4-bromobenzyl)carbamate 
• 26177-44-6 4-bromobenzylamine hydrochloride 
• 59528-27-7 p-iodobenzylamine hydrochloride 
• 34619-03-9 tert-butyldicarbonate 
• 39959-59-6 4-iodobenzyl amine 
• 84250-74-8 (4-iodophenyl)methanamine hydrochloride 
• 16004-15-2 1-bromomethyl-4-iodobenzene 
• 18282-51-4 4-iodo-benzyl alcohol 
• 619-58-9 4-iodobenzoic acid 
• 680190-94-7 1-azidomethyl-4-iodo-benzene 

Downstream Products

• 680190-98-1 tert-butyl N-[4-(2-phenylethynyl)benzyl]carbamate 
• 939378-13-9 3-[(adamantan-1-yloxy)-(1-tert-butyloxycarbonylamino-3-phenylpropyl)phosphinoyl]-2-[4-(tert-butyloxycarbonylaminomethyl)phenylamino]propionic acid 
• 496945-41-6 tert-butyl 4-(2-formylethyl)benzylcarbamate 
• 1269071-39-7 C₁₉H₂₁NO₃S 
• 1381949-73-0 ditert-butyl ((ethyne-1,2-diylbis(4,1-phenylene))bis(methylene))dicarbamate 
• 1482499-10-4 C₂₉H₂₆Fe₂N₂O₇S₂ 
• 680190-97-0 tert-butyl N-[4-(1-hexynyl)benzyl]carbamate 
• 680190-99-2 tert-butyl N-[4-(3,3-dimethyl-1-butynyl)benzyl]carbamate 
• 1025975-03-4 {4-[4-(tert-Butoxycarbonylamino-methyl)-phenylethynyl]-phenyl}-acetic acid methyl ester 
• 189132-02-3 7-[4-(tert-Butoxycarbonylamino-methyl)-phenyl]-hept-6-ynoic acid 
• 773128-23-7 tert-butyl (4-iodobenzyl)(methyl)carbamate 

Relevant articles and documents

Luminescence and Relaxometric Properties of Heteropolymetallic Metallostar Complexes with Selectively Incorporated Lanthanide(III) Ions

The synthesis and characterization of two diethylenetriaminepentaacetic acid (DTPA) based heteropolymetallic metallostar lanthanide complexes with the general formulas (GdL1)3Ln and (GdL2)3Ln are described. The

SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS

Disclosed are 7-phenyl-2-aminoquinoline compounds that are shown to inhibit the biological activity of neuronal nitric oxide synthases (nNOSs). Also disclosed are pharmaceutical compositions comprising the compounds, and methods of using the compounds and

First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate

Inhibition of neuronal nitric oxide synthase (nNOS), an enzyme implicated in neurodegenerative disorders, is an attractive strategy for treating or preventing these diseases. We previously developed several classes of 2-aminoquinoline-based nNOS inhibitor

COMPOUNDS AS MODULATORS OF ROR GAMMA

The present invention encompasses compounds of the formula (I)(I) wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N- oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3', R4, R4', X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

Pyrimidine or pyridine pyridine ketone compound and its preparation method and application (by machine translation)

The invention discloses a kind of type I of the pyrimidine or pyridine pyridine ketone compound and its preparation and application, which belongs to the technical field of pharmaceutical preparation. The compounds have high-efficient and selectively inhibit the cell cycle dependent kinases (Cdks) CDK4 and CDK6 active, and then by inhibiting CDK4/CDK6 prevent tumor cell division. Therefore, the compounds of this invention can be used for CDK4 and CDK6 the involved in cell cycle control disorders result in various diseases, especially suitable for the treatment of malignant tumors. (by machine translation)

COMPOUNDS AS MODULATORS OF ROR GAMMA

The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

Exceptional poly(acrylic acid)-based artificial [FeFe]-hydrogenases for photocatalytic H2 production in water

Light, polymer, action: A set of water-soluble poly(acrylic acid) catalysts PAA-g-Fe2S2 containing {Fe2S2}, an [FeFe]-hydrogenase active-site mimic, is synthesized. This system, combined with CdSe quantum dots a

Degenerate molecular shuttles with flexible and rigid spacers

The preparation and dynamic behavior of degenerate rotaxane molecular shuttles are described in which a benzylic amide macrocycle moves back and forth between two naphthalimide-glycine units along a diphenylethyne spacer or an aliphatic spacer consisting of a C9, C12, or C 26 alkyl chain. Subtle differences in the 1H NMR spectra of the rotaxanes can be related to the presence of conformers in which the macrocycle interacts simultaneously with both glycines, especially in the case of the C9 spacer. The kinetic data of the shuttling behavior in the C26 rotaxane were obtained from dynamic NMR spectroscopy. The Eyring activation parameters were found to be ΔH? = 10 ± 1 kcal mol-1, ΔS? = -6.5 ± 2.0 cal mol-1 K-1, ΔG?298 = 11.9 ± 0.2 kcal mol-1. For the systems with the shorter spacers, the shuttling rates were higher. Also in the diphenylethyne, rotaxane shuttling is rapid on the NMR time scale, indicating that the rigid unit does not impose a large barrier to the translocation of the macrocycle.

THERAPEUTIC MACROLIDE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain macrolide compounds (for convenience, collectively referred to herein as "MC compounds"), which, inter alia, are useful in treatment of cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to treat proliferative conditions such as cancer, and in the treatment of diseases and conditions that are mediated by the regulation (e.g. inhibition) of cell proliferation, optionally in combination with another agent.